NHS hospital invests in ODM equipment

RNS Number : 3065O

Deltex Medical Group PLC

04 November 2016

 

4 November 2016

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

NHS hospital invests in ODM equipment

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce its most substantial account win in a UK NHS hospital for more than two years.

A 450 bed NHS hospital in the South-East of England has acquired six CardioQ-ODM+ monitors and an initial stock of single patient oesophageal probes for use in its peri-operative surgical care. The hospital invested in ODM in response to clinician demand to replace the alternative technology purchased by the Trust as a result of the 2013 NHS national implementation programme for Intra-Operative Fluid Management. The initial order was worth over £30,000 and although this does not alter full year forecasts, it does reflect a generally improving UK performance in the second half of the year to date.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We are encouraged both that groups of clinicians are insisting on using ODM rather than alternative technologies and that NHS hospitals will support these clinicians financially to deliver better outcomes and reduce costs. This order is further evidence of improving trends in our UK business following the launch of the TruFlow probes in May, the presentation of excellent results from the largest ever randomised controlled trial of ODM in June and the further presentation in July of a trial from a major NHS hospital confirming better comparative outcomes from using ODM during surgery."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory	020 3053 8671
Tim Metcalfe Graham Herring Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

NRAVXLFBQFFZFBB